Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

被引：0
|
作者：
Rizzieri, David A. [1 ]
Schiller, Gary J. [2 ]
Solomon, Scott R. [3 ]
Newell, Laura F. [4 ]
Erba, Harry P. [5 ]
Ryan, Robert J. [6 ]
Faderl, Stefan [7 ]
Cortes, Jorge E. [8 ]
Lancet, Jeffrey E. [9 ]
机构：
[1] Duke Comprehens Canc Ctr, Durham, NC USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[3] Northside Hosp Canc Ctr Inst, Leukemia Program, Atlanta, GA USA
[4] Oregon Hlth & Sci Univ, Knight Canc Inst, Hematol & Med Oncol, Portland, OR 97201 USA
[5] Duke Univ, Durham, NC USA
[6] Jazz Pharmaceut, Philadelphia, PA USA
[7] Jazz Pharmaceut, Palo Alto, CA USA
[8] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[9] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2020年 / 26卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
142
引用
收藏
页码：S105 / S106
页数：2
相关论文
共 50 条
  • [1] Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis
    Lancet, Jeffrey E.
    Rizzieri, David A.
    Schiller, Gary J.
    Solomon, Scott R.
    Newell, Laura F.
    Erba, Harry P.
    Ryan, Robert J.
    Faderl, Stefan
    Cortes, Jorge E.
    BLOOD, 2019, 134
  • [2] Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis
    Ryan, Daniel H.
    Newell, Laura F.
    Ritchie, Ellen K.
    Strickland, Stephen A.
    Hogge, Donna E.
    Solomon, Scott R.
    Stone, Richard M.
    Schiller, Gary J.
    Wieduwilt, Matthew J.
    Ryan, Robert J.
    Faderl, Stefan
    Cortes, Jorge E.
    BLOOD, 2019, 134
  • [3] Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis
    Ryan, Daniel H.
    Newell, Laura F.
    Ritchie, Ellen K.
    Strickland, Stephen A.
    Hogge, Donna E.
    Solomon, Scott R.
    Schiller, Gary J.
    Wieduwilt, Matthew J.
    Ryan, Robert J.
    Faderl, Stefan
    Cortes, Jorge E.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S9 - S10
  • [4] Outcomes in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML) Who Achieved Remission with CPX-351 Versus 7+3 Induction: Exploratory Analysis of a Phase 3 Study
    Faderl, Stefan
    Cortes, Jorge E.
    Ritchie, Ellen K.
    Ryan, Robert J.
    Chiarella, Michael
    Schiller, Gary J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S206 - S207
  • [5] Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylating Agent Exposure Who Achieved Remission
    Lin, Tara L.
    Ryan, Daniel H.
    Ritchie, Ellen K.
    Strickland, Stephen A.
    Hogge, Donna E.
    Solomon, Scott R.
    Kolitz, Jonathan E.
    Schiller, Gary J.
    Wieduwilt, Matthew J.
    Ryan, Robert J.
    Faderl, Stefan
    Cortes, Jorge E.
    BLOOD, 2019, 134
  • [6] Outcomes in older patients with high-risk/secondary AML who achieved remission with CPX-351 versus 7+3 but did not undergo transplant: Phase 3 exploratory analysis.
    Lin, Tara L.
    Ryan, Robert J.
    Faderl, Stefan
    Ritchie, Ellen K.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] OVERALL SURVIVAL WITH CPX-351 VERSUS 7+3 IN OLDER ADULTS WITH NEWLY DIAGNOSED, THERAPY-RELATED ACUTE MYELOID LEUKEMIA: SUBGROUP ANALYSIS OF A PHASE 3 STUDY
    Lancet, J. E.
    Rizzieri, D.
    Schiller, G. J.
    Stuart, R. K.
    Kolitz, J. E.
    Solomon, S. R.
    Newell, L. F.
    Erba, H.
    Uy, G. L.
    Ryan, R.
    Chiarella, M.
    Louie, A. C.
    Cortes, J. E.
    HAEMATOLOGICA, 2017, 102 : 214 - 215
  • [8] Efficacy and Safety of CPX-351 versus 7+3 in Older Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (tAML): Subgroup Analysis of a Phase 3 Study
    Lancet, Jeffrey
    Rizzieri, David
    Schiller, Gary
    Stuart, Robert
    Kolitz, Jonathan
    Solomon, Scott
    Newell, Laura
    Erba, Harry
    Uy, Geoffrey
    Ryan, Robert
    Chiarella, Michael
    Louie, Arthur
    Cortes, Jorge
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S288 - S288
  • [9] Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (sAML) with Prior Hypomethylating Agent (HMA) Exposure Who Achieved Remission
    Lin, Tara
    Ryan, Daniel H.
    Ritchie, Ellen K.
    Strickland, Stephen A.
    Hogge, Donna E.
    Solomon, Scott R.
    Kolitz, MDJonathan E.
    Schiller, Caryl
    Wieduwilt, Matthew J.
    Ryan, Robert J.
    Fader, Stefan
    Cortes, Jorge E.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S102 - S102
  • [10] Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 Versus Conventional Chemotherapy
    Kolitz, Jonathan E.
    Ryan, Daniel H.
    Newell, Laura F.
    Strickland, Stephen A.
    Hogge, Donna E.
    Solomon, Scott R.
    Schiller, Gary J.
    Ryan, Robert J.
    Faderl, Stefan
    Cortes, Jorge E.
    BLOOD, 2019, 134
12345